Neuphoria Therapeutics to receive $15M payment from Merck

Neuphoria Therapeutics (NEUP) announced that the Company is due to receive a $15M milestone payment from Merck (MRK), known as MSD outside the United States and Canada. The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an alpha7 nicotinic acetylcholine receptor positive allosteric modulator, for the treatment of the symptoms of Alzheimer’s disease dementia